WT1 regulates the expression of the major glomerular podocyte membrane protein Podocalyxin

被引:146
作者
Palmer, RE
Kotsianti, A
Cadman, B
Boyd, T
Gerald, W
Haber, DA [1 ]
机构
[1] Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA
[2] Harvard Univ, Sch Med, Charlestown, MA 02129 USA
[3] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA
[4] Baystate Med Ctr, Dept Pathol, Springfield, MA 01199 USA
关键词
D O I
10.1016/S0960-9822(01)00560-7
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The WT1 tumor suppressor gene encodes a zinc finger transcription factor expressed in differentiating glomerular podocytes. Complete inactivation of WT1 in the mouse leads to failure of mesenchymal induction and renal agenesis, an early developmental phenotype that prevents analysis of subsequent stages in glomerular differentiation [1]. In humans with Denys-Drash Syndrome, a heterozygous germline mutation in WT1 is associated with specific defects in glomeruli and an increased risk for developing Wilms Tumor [2, 3]. WT1 target genes implicated in cell cycle regulation and cellular proliferation have been proposed [4], but the link between WT1 function and glomerular differentiation is unexplained. Here, we show that inducible expression of WT1 in rat embryonic kidney cell precursors leads to the induction of endogenous Podocalyxin, the major structural membrane protein of glomerular podocytes, which is implicated in the maintenance of filtration slits. Binding of WT1 to conserved elements within the Podocalyxin gene promoter results in potent transcriptional activation, and the specific expression pattern of Podocalyxin in the developing kidney mirrors that of WT1 itself. These observations support a role for WT1 in the specific activation of a glomerular differentiation program in renal precursors and provide a molecular basis for the glomerulonephropathy that is characteristic of Denys-Drash Syndrome.
引用
收藏
页码:1805 / 1809
页数:5
相关论文
共 22 条
[1]   Donor splice-site mutations in WT1 are responsible for Frasier syndrome [J].
Barbaux, S ;
Niaudet, P ;
Gubler, MC ;
Grunfeld, JP ;
Jaubert, F ;
Kuttenn, F ;
Fekete, CN ;
SouleyreauTherville, N ;
Thibaud, E ;
Fellous, M ;
McElreavey, K .
NATURE GENETICS, 1997, 17 (04) :467-470
[2]   Anuria, omphalocele, and perinatal lethality in mice lacking the CD34-related protein podocalyxin [J].
Doyonnas, R ;
Kershaw, DB ;
Duhme, C ;
Merkens, H ;
Chelliah, S ;
Graf, T ;
McNagny, KM .
JOURNAL OF EXPERIMENTAL MEDICINE, 2001, 194 (01) :13-27
[3]   The Wilms tumor suppressor WT1 directs stage-specific quiescence and differentiation of human hematopoietic progenitor cells [J].
Ellisen, LW ;
Carlesso, N ;
Cheng, T ;
Scadden, DT ;
Haber, DA .
EMBO JOURNAL, 2001, 20 (08) :1897-1909
[4]   ALTERNATIVE SPLICING AND GENOMIC STRUCTURE OF THE WILMS-TUMOR GENE-WT1 [J].
HABER, DA ;
SOHN, RL ;
BUCKLER, AJ ;
PELLETIER, J ;
CALL, KM ;
HOUSMAN, DE .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (21) :9618-9622
[5]  
HABIB R, 1985, CLIN NEPHROL, V24, P269
[6]   Two splice variants of the Wilms' tumor 1 gene have distinct functions during sex determination and nephron formation [J].
Hammes, A ;
Guo, JK ;
Lutsch, G ;
Leheste, JR ;
Landrock, D ;
Ziegler, U ;
Gubler, MC ;
Schedl, A .
CELL, 2001, 106 (03) :319-329
[7]   Identification of podocalyxin-like protein 1 as a novel cell surface marker for hemangioblasts in the murine aorta-gonad-mesonephros region [J].
Hara, T ;
Nakano, Y ;
Tanaka, M ;
Tamura, K ;
Sekiguchi, T ;
Minehata, K ;
Copeland, NG ;
Jenkins, NA ;
Okabe, M ;
Kogo, H ;
Mukouyama, Y ;
Miyajima, A .
IMMUNITY, 1999, 11 (05) :567-578
[8]  
HERZLINGER D, 1993, J CELL SCI, P61
[10]   IDENTIFICATION AND CHARACTERIZATION OF PODOCALYXIN - THE MAJOR SIALOPROTEIN OF THE RENAL GLOMERULAR EPITHELIAL-CELL [J].
KERJASCHKI, D ;
SHARKEY, DJ ;
FARQUHAR, MG .
JOURNAL OF CELL BIOLOGY, 1984, 98 (04) :1591-1596